<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MESALAMINE <img border="0" src="../images/pr.gif"/></span><br/>(me-sal'a-meen)<br/><span class="topboxtradename">Asacol, </span><span class="topboxtradename">Canasa, </span><span class="topboxtradename">Rowasa, </span><span class="topboxtradename">Salofalk <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Pentasa<br/></span><b>Classifications:</b> <span class="classification">skin and mucous membrane agent</span>; <span class="classification">antiinflammatory</span>; <span class="classification">prostaglandin inhibitor</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg controlled release capsule (Pentasa); 400 mg delayed release tablet (Asacol); 500 mg suppository, 4 g/60 mL rectal suspension (Rowasa); 500 mg suppositories (Canasa)</p>
<h1><a name="action">Actions</a></h1>
<p>Thought to diminish inflammation by blocking cyclooxygenase and inhibiting prostaglandin synthesis in the colon.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Provides topical antiinflammatory action in the colon of patients with ulcerative colitis.</p>
<h1><a name="uses">Uses</a></h1>
<p>Indicated in active mild to moderate distal ulcerative colitis, proctosigmoiditis, or proctitis; maintenance of remission
         of ulcerative colitis.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Crohn's disease.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to mesalamine, aminosalicylates, or salicylates.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment, renal disease, renal failure, pregnancy (category B), lactation; older adults; sulfite hypersensitivity;
         sensitivity to sulfasalazine.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Ulcerative Colitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Rectal</span> (Rowasa) 4 g once/d h.s., enema should be retained for about 8 h if possible or 1 suppository (500 mg) b.i.d.; (Canasa) 500
               mg b.i.d., may increase up to 500 mg t.i.d. <span class="rdroute">PO</span> (Asacol) 800 mg t.i.d. times 6 wk; (Pentasa) 500 mg t.i.d. times 6 wk. <span class="rdroute">Maintenance Dose</span> (Asacol) 800 mg b.i.d. or 400 mg q.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 50 mg/kg/d divided q612h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Ensure that controlled-release and enteric forms of the drug are not crushed or chewed.</li>
<li>Shake the bottle well to make sure the suspension is mixed.</li>
</ul><span class="adminroutetype">Rectal</span><br/><ul>
<li>Use rectal suspension at bedtime with the objective of retaining it all night.</li>
<li>Store at 15°30° C (59°86° F) away from heat and light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> <span class="speceff-common">Headache,</span> fatigue, asthenia, malaise, weakness, dizziness. <span class="typehead">GI:</span> <span class="speceff-common">Abdominal pain, cramps,</span> or <span class="speceff-common">discomfort,</span> flatulence, nausea, diarrhea, constipation, hemorrhoids, rectal pain, hepatitis (rare). <span class="typehead"> Skin:</span> Sensitivity reactions, rash, pruritus, alopecia. <span class="typehead">Body as a Whole:</span> Fever. <span class="typehead">Hematologic:</span> Thrombocytopenia (rare), eosinophilia. <span class="typehead">Urogenital:</span> Interstitial nephritis. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> PR 535% absorbed from colon depending on retention time of enema or suppository. PO Asacol, approximately 28%
      absorbed; 80% of drug is released in colon 12 h after ingestion. PO Pentasa, 50% of drug is released in colon at a
      pH Peak: 36 h. <span class="typehead">Distribution:</span> Rectal administration may reach as high as the ascending colon. Asacol is released in the ileum and colon; Pentasa is released
      in the jejunum, ileum, and colon. Low concentrations of mesalamine and higher concentrations of its metabolites are excreted
      in breast milk. <span class="typehead">Metabolism:</span> Rapidly acetylated in the liver and colon wall. <span class="typehead"> Elimination:</span>  Excreted primarily in feces; absorbed drug excreted in urine. <span class="typehead">Half-Life:</span> 215 h (depending on formulation). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor carefully urinalysis, BUN, and creatinine, especially in patients with preexisting kidney disease. The
            kidney is the major target organ for toxicity.
         </li>
<li>Assess for S&amp;S of allergic-type reactions (e.g., hives, itching, wheezing, anaphylaxis). Suspension contains a sulfite that
            may cause reactions in asthmatics and some nonasthmatic persons.
         </li>
<li>Expect response to therapy within 321 d; however, the usual course of therapy is from 36 wk depending on symptoms
            and sigmoidoscopic examinations.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report to physician promptly: Cramping, abdominal pain, or bloody diarrhea, which are indications for immediate drug withdrawal.</li>
<li>Check with doctor if rectal irritation (e.g., bleeding, blistering, pain, burning, itching) occurs while using this drug.</li>
<li>Check with physician before using any new medicine (prescription or OTC).</li>
<li>Continue medication for full time of treatment even if you are feeling better.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>